Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma

Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma

Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers. However, no reliable biomarker of survival or response has entered the clinic to identify those patients with melanoma who are most likely to benefit from ICIs. Glycosylation affe...

Full description

Bibliographic Details
Main Authors: Alessia Visconti, Niccolò Rossi, Helena Deriš, Karla A Lee, Maja Hanić, Irena Trbojević-Akmačić, Andrew M. Thomas, Laura A. Bolte, Johannes R. Björk, Jahlisa S. Hooiveld-Noeken, Ruth Board, Mark Harland, Julia Newton-Bishop, Mark Harries, Joseph J. Sacco, Paul Lorigan, Heather M. Shaw, Elisabeth G.E. de Vries, Rudolf S.N. Fehrmann, Rinse K. Weersma, Tim D. Spector, Paul Nathan, Geke A. P. Hospers, Peter Sasieni, Veronique Bataille, Gordan Lauc, Mario Falchi
Format: Article
Language:English
Published: BMC 2023-02-01
Series:BMC Cancer
Subjects:
Melanoma
Immune checkpoint inhibitors
Total serum N-glycomics
Response
Survival
Online Access:https://doi.org/10.1186/s12885-023-10511-3

Internet

https://doi.org/10.1186/s12885-023-10511-3

Similar Items